RE: RE: RE: Why
First off that is a much better post, gave some intelligent comments without ripping other people. Now a CR in first line patients is not all that much to ask, the cancer can come back but to have knockout results you need some of those. Second the response rate is comparable to other sudies it does not beat it, I have read a number over the past year. The one good result is stable disease, 90% is very good, but if it's only a few months a partner will not be impressed. I admit that my expectations for the lung trial may have been unrealistic.
You say the market is a joke, but I bet if it was going up you would say the market knows something. I still think we get approved in Head and Neck. I hope we do significant better in Squamous cell. I predicted awhile back that the next trial would be squamous if only one trial in lung could proceed and I'm even more sure now!
Yes the Biovex takeover does give evidence of ONCY being undervalued but I don't see what is going to push us in the next few months.?